Cardiotoxicity is a serious side-effect of the antineoplastic ANTHRACYCLINES. Kilickap et al. have recently investigated whether serum levels of CARDIAC TROPONIN T (CTNT), associated with myocardial ...

Combining anthracycline and taxane for early-stage operable breast cancer was more effective than either anthracycline or taxane chemotherapy alone in reducing breast cancer recurrence and death, ...

Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib The Children’s Oncology Group AAML0631 ...

Anthracyclines are a class of chemotherapies effective in treating many forms of cancer, including leukemias, lymphomas and breast cancer. Anthracyclines - such as doxorubicin, frequently used against ...

Efficacy of High-Dose Chemotherapy and Three-Dimensional Conformal Radiation for Atypical Teratoid/Rhabdoid Tumor: A Report From the Children’s Oncology Group Trial ACNS0333 Capecitabine was of ...

Adding an anthracycline to adjuvant chemotherapy for TOP2A-normal early breast cancer significantly improved disease-free survival (DFS) but not overall survival (OS) at 10 years, and doubled the risk ...

Please provide your email address to receive an email when new articles are posted on . A decrease in left ventricular ejection fraction to below normal levels occurred more frequently among women ...

In young adults with acute myeloid leukemia (AML), intensification of the anthracycline dose during induction therapy has improved the rate of complete remission but not of overall survival. We ...

Anthracyclines are widely used to treat hematological and solid-tumor cancers, but past research suggests their use may be associated with late cardiac effects, including heart failure, among patients ...

For patients with triple-negative breast cancer (TNBC), neoadjuvant carboplatin plus docetaxel yields the same pathologic complete response and survival rates as a ...

IRVINE, Calif. and AMSTERDAM, January 20, 2026--(BUSINESS WIRE)--Agendia, Inc., a leader in precision oncology for breast cancer, today announced that the updated NCCN Clinical Practice Guidelines in ...